Drug-Drug Interaction Pattern Recognition

Abstract

Background and Objective: Drug-drug interaction (DDI) is an important aspect of drug development, especially for safety. When a drug is used concomitantly with other drug(s), one of the major concerns is the change of exposures, including the rate and extent of drug absorption, distribution, metabolism and elimination. To address the concerns, a common practice is to measure and report the differences between the exposure in the presence and in the absence of concomitant medication (COMED). The area under the plasma concentration versus time curve (AUC), maximum plasma concentration (Cmax) and time to reach the Cmax (tmax) changes are usually measured in DDI studies. A usual observation is the different extents of changes among AUC, Cmax and tmax, which may raise concerns in certain therapeutic areas or some special agents. The objective of this study was to investigate the variation among changes of AUC, Cmax and tmax in DDI studies, and its pharmacokinetic manifestation.Data Sources: Based on a list of DDI results from the literature, with the assumptions that the primary parameters of a drug of interest were altered during a DDI, two sets of simulated data were generated according to a single oral dose, one-compartment model. The first set including 24 cases with different half-lives and absorption constants (ka) considered the exposure changes upon independent variation of bioavailability (F), clearance (CL), volume of distribution (Vd) and ka up to 50-fold increases or decreases. The second set considered the exposure changes with simultaneous variation of F, CL, Vd, and ka within 5-fold range (increase or decrease) for a case selected from the first set.Study Selection, Data Extraction and Synthesis: Parameter fold changes (defined in a fashion showing fold increase or fold decreases, including CL fold change, F fold change, Vd fold change and ka fold change) and exposure changes (AUC fold change, Cmax fold change, tmax fold change and fold change difference [AUC fold change — Cmax fold change]) were used to generate plots demonstrating various relationships between parameter fold changes and exposure changes. Based on the observations that AUC was influenced by CL and F, Cmax was affected by all four parameters, tmax was mainly determined by CL and ka, F did little for tmax and ka was unrelated to AUC, a chart was created for DDI pattern recognition.Conclusion: An approach, named DDI pattern recognition, is proposed for didactical purposes. It provides a quick initial estimate for interpreting the DDI results based on the exposure changes. This approach entails the following stages: (i) performing a drug interaction study; (ii) calculating the exposure changes in the presence of COMED compared to those in the absence of COMED, and the fold change difference; (iii) selecting the parameter fold changes that may play important roles in a specific DDI, by estimating their possible ranges; and (iv) interpreting the DDI by integrating all the information available, such as the possible mechanism involved. A quic...

Peculiar Velocity Constraints From Five-Band Sz Effect Measurements Toward Rx J1347.5−1145 With Music and Bolocam From the Cso

“…The output from each antenna array is then coupled to four separate microwave kinetic inductance detectors (MKIDs), with three-pole lumped element filters defining a different observing band for each MKID (Kumar et al 2009;Duan 2015). These four observing bands are centered at 147,213,281,and 337 GHz,14 and they have corresponding point spread functions (PSFs) that are approximately Gaussian and have full-width half maxima (FWHM) of 48, 36, 32, and 29.…”

Pattern Recognition in Pharmacodynamic Data Analysis

“…These correspond to patterns typically encountered in in vivo pharmacodynamic practice and which to a great extent can be characterized by means of turnover models (3,4). 1 In some cases, alternative models (other permutations of the proposed turnover model or link models or binding on/off models) may be more appropriate. The diagram in Fig.…”

“…Case studies 18 and 19 exhibit clear rebound patterns, whereas in case studies 17 and 20, response approaches the baseline monotonically due to slow plasma kinetics (t 1/2 plasma > t 1/2 response). Case studies 17-20 are 1 Some of the datasets are generously shared by different companies under confidentiality terms; hence, their therapeutic origin or mechanism of action is not revealed. Needless to say, ideally, information about the study designs, pharmacological mechanism(s), and/or true variability in the original data would have improved the analysis.…”

“…Pattern recognition is a pivotal activity when modeling pharmacodynamic data, because a rigorous strategy is essential for dissecting the determinants behind response-time courses. In the pharmacology field, pattern recognition has also been proposed for interpreting results of drug-drug interactions and pharmacokinetic data (1,2). To inspire young kineticists beyond the slavery of computers, we have practiced pattern recognition over three decades in our pharmacology teaching.…”

Pattern Recognition in Pharmacokinetic Data Analysis

“…Pattern recognition is a pivotal activity when modeling pharmacokinetic data, because a rigorous strategy is essential for dissecting the determinants behind concentration-time courses. In the pharmacology field, pattern recognition has also been proposed for interpreting results of drug-drug interactions (1).…”